AIM
CALA

Advantage Investment Management’s Calithera Biosciences, Inc CALA Stock Holding History

Advantage Investment Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-50
Closed -$12K – 1138
2017
Q1 		$12K Sell
50
-115
-70% -$19.9K ﹤0.01% 661
2016
Q4 		$11K Sell
165
-100
-38% -$6.25K ﹤0.01% 620
2016
Q3 		$17K Sell
265
-100
-27% -$6.45K 0.01% 534
2016
Q2 		$27K Hold
365
– – 0.01% 437
2016
Q1 		$41K Buy
365
+25
+7% +$2.83K 0.02% 361
2015
Q4 		$52K Buy
340
+25
+8% +$3.75K 0.03% 331
2015
Q3 		$34K Buy
+315
New +$40.8K 0.02% 371

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Advantage Investment Management's CALA Position: Q2 2017 in Review

Advantage Investment Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2017, closing a stake of 50 shares — an estimated $12K sold.

Advantage Investment Management first reported a position in CALA in Q3 2015 and held it in 7 quarters. The position peaked at $52K in Q4 2015. 94 funds tracked by Wall St. Rank hold CALA as of Q2 2017.

  • Advantage Investment Management reported no remaining Calithera Biosciences, Inc position as of Q2 2017 after selling out during the quarter.
  • Advantage Investment Management sold 50 Calithera Biosciences, Inc shares in Q2 2017, an estimated $12K.
  • Advantage Investment Management first reported a position in Calithera Biosciences, Inc in Q3 2015 and held it in 7 quarters.
  • Advantage Investment Management's Calithera Biosciences, Inc position peaked at $52K in Q4 2015.
  • 94 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2017.

Based on Advantage Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.